Patents Examined by Sudhakar Katakam
  • Patent number: 11406683
    Abstract: The invention relates to novel compounds with the ability to link an immune response to a pathogen, to the use of said compounds in a disease or disorder mediated and/or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: August 9, 2022
    Assignee: CENTAURI THERAPEUTICS LIMITED (GB/GB)
    Inventors: Michael Westby, Melanie Glossop, Christine Watson
  • Patent number: 11401304
    Abstract: The present invention relates to cyclic NTCP targeting peptides which are preS-derived peptides of hepatitis B virus (HBV). The present invention further relates to pharmaceutical compositions comprising at least one cyclic peptide. The present invention further relates to medical uses of said cyclic peptides and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a liver disease or condition and/or the inhibition of HBV and/or HDV infection.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: August 2, 2022
    Assignee: RUPRECHT-KARLS-UNIVERSIT√ĄT HEIDELBERG
    Inventors: Stephan Urban, Yi Ni, Walter Mier
  • Patent number: 11400130
    Abstract: The present invention relates to series of compounds as an inhibitor targeting Proliferating Cell Nuclear Antigen (PCNA). Pharmaceutical compositions of those compounds and methods of using them in the treatment of cancer are within the scope of this disclosure.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: August 2, 2022
    Assignee: Purdue Research Foundation
    Inventors: Vincent Jo Davisson, Matthew David Bartolowits, Jonathon Michael Gast
  • Patent number: 11400131
    Abstract: The invention relates to a specific peptide combination. The peptide combination may be present in a pharmaceutically acceptable composition. The peptide combination can be used in the therapy or prevention of Type 1 Diabetes (TID). The invention also relates to a method of diagnosing or determining treatment efficacy, the method utilising the specific peptide combination.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: August 2, 2022
    Assignee: King's College London
    Inventor: Mark Peakman
  • Patent number: 11401235
    Abstract: The present invention relates novel methods of synthesizing terphenyl compounds and in particular to novel methods for the synthesis of a compound of Formula I or intermediates thereof.
    Type: Grant
    Filed: July 1, 2020
    Date of Patent: August 2, 2022
    Assignee: VECTUS BIOSYSTEMS LIMITED
    Inventors: Anthony Kaye, Nurul Quazi, George Feast, Marshnil Lakshman
  • Patent number: 11395845
    Abstract: The present disclosure relates to a method of treating prostate cancer comprising administering to a subject in need thereof a therapeutically effective amount of a vasopressin analogue.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: July 26, 2022
    Assignee: SUNNYBROOK RESEARCH INSTITUTE
    Inventors: Laurence H. Klotz, Vasundara Venkateswaran
  • Patent number: 11398645
    Abstract: Processes and reaction mixtures including non-aqueous solvent mixtures are presented. Non-aqueous solvent mixtures including fluoride salt and non-aqueous solvent combinations are provided that possess high fluoride ion concentrations useful for a range of applications, including organic synthesis. Further non-aqueous solvent mixtures are provided including a salt possessing a non-fluoride anion and a non-aqueous solvent that, when contacted with aqueous fluoride-containing reagents, extract fluoride ions to form non-aqueous fluoride-ion solutions possessing high fluoride-ion concentrations. The salts include an organic cation that does not possess a carbon in the ?-position or does not possess a carbon in the ?-position having a bound hydrogen. This salt structure facilitates its ability to be made anhydrous without decomposition. Example anhydrous fluoride salts include (2,2-dimethylpropyl)trimethylammonium fluoride and bis(2,2-dimethylpropyl)dimethylammonium fluoride.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: July 26, 2022
    Assignees: California Institute of Technology, The Regents of the University of California
    Inventors: Simon C. Jones, Victoria K. Davis, Christopher M. Bates, Nebojsa Momcilovic, Brett M. Savoie, Michael A. Webb, Thomas F. Miller, III, Robert H. Grubbs, Jennifer M. Murphy
  • Patent number: 11396533
    Abstract: The present invention provides a process for the manufacture of GLP-1 analogues with high yield and purity by fragment condensation on the solid phase. In particular, it describes a convergent synthesis by condensation of a C-terminal pseudoproline fragment A with a fragment B bound to a solid support, followed by deprotection and cleavage from the support and final purification to yield the desired peptide. The invention further provides intermediates useful in the manufacturing process.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: July 26, 2022
    Assignee: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Giuseppina Maria Incisivo, Andrea Orlandin, Antonio Ricci, Ivan Guryanov, Walter Cabri
  • Patent number: 11389513
    Abstract: The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, particularly anterior and posterior segment ocular diseases and physical disorders, paraocular and extraocular diseases and physical disorders, and nerve or nervous system diseases and physical disorders, as well as methods of manufacturing such compositions. The invention also provides medical devices comprising one or more such compositions of the invention.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: July 19, 2022
    Assignee: SUSTAIN HOLDINGS, LLC
    Inventors: Richard E. Schlumpf, Robert Baratta, Shawn Delorey, David J. Calkins
  • Patent number: 11389510
    Abstract: The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC50 that is at least 20-fold higher than the EC50 of the corresponding free CNP agonist and which released CNP agonist has an EC50 that is at most 3-fold higher than the EC50 of the corresponding free CNP agonist; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: July 19, 2022
    Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/S
    Inventors: Kennett Sprog√łe, Harald Rau, Felix Cleemann, Ulrich Hersel, Caroline Elisabeth Rasmussen
  • Patent number: 11389541
    Abstract: Described herein are drug delivery systems for delivering biologically active agents comprising primary or secondary amines, or a ring nitrogen atom of an azaheteroaryl ring, pharmaceutically acceptable salts thereof, drug delivery reagents related thereto, pharmaceutical compositions comprising the drug delivery systems, and the use of the drug delivery systems as sustained release therapeutics.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: July 19, 2022
    Assignee: NOVARTIS AG
    Inventors: Christopher M. Adams, Myriam April, Tanzina Fazal, Cornelia Jutta Forster, Nicole Gerwin, Edward Charles Hall, Jean-Baptiste Georges Armand Langlois, Cameron Chuck-munn Lee
  • Patent number: 11390653
    Abstract: An amino acid-specific binder selectively binds to a binding amino acid. A binder complex selectively identifies the binding amino acid and includes an adjunct attached to the amino acid-specific binder. The adjunct includes a taggant, protein, substrate, or chemical modifier. Selectively identifying an N-terminal amino acid includes anchoring a C-terminal end; contacting an N-terminal amino acid of the anchored analyte with the binder complex; selectively binding when the N-terminal amino acid includes the binding amino acid; producing, by the taggant of the tagged complex, a taggant signal; detecting the taggant signal; and identifying the N-terminal amino acid based on the taggant signal.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: July 19, 2022
    Assignee: GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF COMMERCE
    Inventors: Jennifer A. Tullman, Zvi Kelman, John P. Marino
  • Patent number: 11390579
    Abstract: The invention concerns a new, efficient process for the preparation of enantiomerically pure norepinephrine (also known as noradrenaline), or an addition salt thereof, using a catalytic hydrogenation system under hydrogen donor transfer. The invention also discloses a novel intermediate and the process for the preparation thereof.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: July 19, 2022
    Assignee: Edmond Pharma, s.r.l.
    Inventors: Matteo Zacche', Pier Andrea Gatti, Fulvio Gerli, Davide Sbarbada, Fabio Rondina
  • Patent number: 11376304
    Abstract: The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: July 5, 2022
    Assignee: STEALTH BIOTHERAPEUTICS INC.
    Inventor: D. Travis Wilson
  • Patent number: 11376302
    Abstract: Methods for treating depression in, and decreasing a dose of ketamine given to, a subject in need thereof, comprising, administering a CaMKII inhibitor are provided.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: July 5, 2022
    Assignee: CARMEL HAIFA UNIVERSITY ECONOMIC CORPORATION LTD.
    Inventors: Yaacov Rozenblum, Elham Taha, Chinnakkaruppan Adaikkan
  • Patent number: 11377416
    Abstract: The present invention provides novel, stable, processable and pharmaceutically acceptable salt forms of 2R,6R-hydroxynorketamine or 2S,6S-hydroxynorketamine with high aqueous solubility.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: July 5, 2022
    Assignee: SMALL PHARMA LTD.
    Inventors: David Pearson, Lorraine Sharp, Alan Armstrong, Richard Myerson, Jonathan Hull, Paul Blaney, Peter Rands, Marie Layzell, Zelah Joel
  • Patent number: 11369586
    Abstract: Described herein are antifungal peptoids, the development and characterization of the antifungal peptoids, methods of making the antifungal peptoids, and methods of using the antifungal peptoids. In some embodiments, the antifungal peptoids may be administered to a subject infected with or at risk of being infected with pathogenic fungi including, for example Cryptococcus spp. In some embodiments, the Cryptococcus spp. may include C. neoformans or C. gattii or both.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: June 28, 2022
    Assignee: Middle Tennessee State University
    Inventors: Kevin L. Bicker, Madyson P. Middleton, Scott A. Armstrong
  • Patent number: 11370823
    Abstract: Compositions and provided to induce cells of the inner ear to renter the cell cycle and to proliferate. In particular, hair cells are induced to proliferate by administration of a composition which activates the Myc and Notch. Supporting cells are induced to transdifferentiate to hair cells by inhibition of Myc and Notch activity or the activation of Atoh1. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: June 28, 2022
    Assignees: Massachusetts Eye and Ear Infirmary, President and Fellows of Harvard College
    Inventors: Zheng-Yi Chen, David R. Liu, Margie Li, David B. Thompson, John Zuris
  • Patent number: 11370740
    Abstract: The present invention provides a novel method for producing an ester group-containing compound and a derivative produced using the compound as a synthetic intermediate. The invention also provides a polymerizable composition containing the compound obtained by the production method and a film-shaped polymer obtained by polymerizing the polymerizable composition. The present invention is a method for producing an ester group-containing compound, the method including a mixing step of mixing a condensing agent, a Bronsted acid, a carboxylic acid, and a phenol or an alcohol to prepare a reaction mixture. The Bronsted acid selected is other than the condensing agent, the carboxylic acid, and the phenol.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: June 28, 2022
    Assignee: DIC CORPORATION
    Inventors: Masahiro Horiguchi, Toru Tsuruta
  • Patent number: 11370666
    Abstract: A method of preparing pentachlorodisilane is disclosed. The method comprises partially reducing hexachlorodisilane with a metal hydride compound to give a reaction product comprising pentachlorodisilane. The method further comprises purifying the reaction product to give a purified reaction product comprising the pentachlorodisilane. The purified reaction product comprising pentachlorodisilane formed in accordance with the method is also disclosed.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: June 28, 2022
    Assignee: Jiangsu Nata Opto-Electronic Materials Co. Ltd.
    Inventors: Barry Ketola, Noel Mower Chang, Jeanette Young, Xiaobing Zhou